Patent: 9,562,223
✉ Email this page to a colleague
Summary for Patent: 9,562,223
| Title: | Methods for reducing intraocular pressure by administering a soluble hyaluronidase glycoprotein (sHASEGP) |
| Abstract: | Provided are methods for reducing intraocular pressure in the eye of a subject by administering neutral active soluble active hyaluronidase glycoproteins (sHASEGPs) and modified forms thereof to the eye. The sHASEGPs are soluble forms of human PH20 hyaluronidase. Also provided are the sHASEGPs, methods of manufacture, and uses thereof. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described. The sHASEGPs include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. |
| Inventor(s): | Bookbinder; Louis (San Diego, CA), Kundu; Anirban (San Diego, CA), Frost; Gregory I. (Palm Beach, FL) |
| Assignee: | Halozyme, Inc. (San Diego, CA) |
| Application Number: | 13/999,454 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,562,223
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Bausch & Lomb Incorporated | VITRASE | hyaluronidase | Injection | 021640 | May 05, 2004 | ⤷ Sign Up | 2023-03-05 |
| Bausch & Lomb Incorporated | VITRASE | hyaluronidase | Injection | 021640 | December 02, 2004 | ⤷ Sign Up | 2023-03-05 |
| Amphastar Pharmaceuticals, Inc. | AMPHADASE | hyaluronidase | Injection | 021665 | October 26, 2004 | ⤷ Sign Up | 2023-03-05 |
| Akorn, Inc. | HYDASE | hyaluronidase | Injection | 021716 | October 25, 2005 | ⤷ Sign Up | 2023-03-05 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
